ONCOLOGY Vol 35, Issue 12 | Oncology

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

December 22, 2021

Original Research

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.

Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma

December 20, 2021

Case Study

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.

Expert Commentary on the Product Profile of Loncastuximab Tesirine

December 16, 2021

Product Profile

In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.

Adjuvant Systemic Therapy Trends in 2021

December 09, 2021


As always, keep up with the latest issue of ONCOLOGY® to stay up-to-date on the latest practical and timely clinical information necessary to deliver the highest level of patient care.